
Core Scientific (CORZZ) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
79.5M
Gross Profit
8.2M
10.33%
Operating Income
-42.6M
-53.56%
Net Income
580.7M
730.20%
Balance Sheet Metrics
Total Assets
1.6B
Total Liabilities
1.8B
Shareholders Equity
-181.5M
Cash Flow Metrics
Operating Cash Flow
590.7M
Free Cash Flow
-129.1M
Revenue & Profitability Trend
Core Scientific Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 510.7M | 502.4M | 640.3M | 544.5M | 60.3M |
Cost of Goods Sold | 389.6M | 378.9M | 631.9M | 305.6M | 50.9M |
Gross Profit | 121.1M | 123.5M | 8.4M | 238.9M | 9.4M |
Gross Margin % | 23.7% | 24.6% | 1.3% | 43.9% | 15.6% |
Operating Expenses | |||||
Research & Development | 11.8M | 7.2M | 27.0M | 7.7M | 5.3M |
Selling, General & Administrative | 120.4M | 100.9M | 226.0M | 64.5M | 16.3M |
Other Operating Expenses | 1.1M | - | - | - | - |
Total Operating Expenses | 133.3M | 108.1M | 253.0M | 72.2M | 21.6M |
Operating Income | -12.2M | 15.3M | -244.6M | 166.6M | -12.2M |
Operating Margin % | -2.4% | 3.1% | -38.2% | 30.6% | -20.2% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | - |
Interest Expense | 37.1M | 86.2M | 96.8M | 44.4M | 4.4M |
Other Non-Operating Income | -1.3B | -174.9M | -1.8B | -59.2M | 4.4M |
Pre-tax Income | -1.3B | -245.8M | -2.2B | 63.1M | -12.2M |
Income Tax | 859.0K | 683.0K | -17.1M | 15.8M | 0 |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 25.0% | 0.0% |
Net Income | -1.3B | -246.5M | -2.1B | 47.3M | -12.2M |
Net Margin % | -257.5% | -49.1% | -335.2% | 8.7% | -20.2% |
Key Metrics | |||||
EBITDA | 108.2M | 114.3M | -210.6M | 184.0M | -2.9M |
EPS (Basic) | - | - | - | - | - |
EPS (Diluted) | - | - | - | - | - |
Basic Shares Outstanding | - | - | - | - | - |
Diluted Shares Outstanding | - | - | - | - | - |
Income Statement Trend
Core Scientific Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 836.2M | 50.4M | 15.9M | 117.9M | 8.7M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 1.0M | 1.0M | 257.0K | 1.7M | 792.0K |
Inventory | - | - | - | - | - |
Other Current Assets | 66.0M | 5.3M | 1.0M | 236.5M | 2.8M |
Total Current Assets | 904.0M | 97.0M | 85.1M | 756.6M | 70.9M |
Non-Current Assets | |||||
Property, Plant & Equipment | 614.1M | 517.0M | 536.5M | 60.4M | 25.9M |
Goodwill | - | 2.2M | 1.7M | 2.1B | 123.2M |
Intangible Assets | - | - | 1.7M | 8.2M | 6.7M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 24.0M | 19.6M | 9.3M | 12.0M | 349.0K |
Total Non-Current Assets | 694.9M | 615.1M | 722.6M | 1.7B | 154.7M |
Total Assets | 1.6B | 712.2M | 807.7M | 2.4B | 225.6M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 19.3M | 154.8M | 53.6M | 11.6M | 3.1M |
Short-term Debt | 27.9M | 144.2M | 37.0M | 104.4M | 18.2M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 17.6M | 6.8M | 1.6M | 4.4M | 1.0M |
Total Current Liabilities | 134.6M | 488.4M | 186.8M | 320.3M | 69.6M |
Non-Current Liabilities | |||||
Long-term Debt | 1.2B | 721.3M | 720.0K | 714.4M | 22.1M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 15.3M | 99.3M | 1.0B | 18.5M | 103.0K |
Total Non-Current Liabilities | 2.3B | 820.7M | 1.0B | 777.4M | 66.7M |
Total Liabilities | 2.4B | 1.3B | 1.2B | 1.1B | 136.4M |
Equity | |||||
Common Stock | 3.0K | 36.0K | 36.0K | 27.0K | 1.0K |
Retained Earnings | -3.7B | -2.4B | -2.2B | -27.4M | -74.7M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | -820.2M | -596.9M | -409.3M | 1.3B | 89.2M |
Key Metrics | |||||
Total Debt | 1.2B | 865.5M | 37.7M | 818.8M | 40.3M |
Working Capital | 769.4M | -391.4M | -101.7M | 436.3M | 1.3M |
Balance Sheet Composition
Core Scientific Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -1.3B | -246.5M | -2.1B | 47.3M | -12.2M |
Depreciation & Amortization | 120.1M | 96.4M | 226.1M | 33.4M | 9.4M |
Stock-Based Compensation | 51.9M | 58.9M | 182.9M | 38.9M | 3.0M |
Working Capital Changes | -9.1M | 441.4M | 359.4M | 172.8M | 34.3M |
Operating Cash Flow | -1.4B | -30.8M | -1.8B | 120.2M | 29.7M |
Investing Activities | |||||
Capital Expenditures | -95.0M | -2.2M | -601.7M | 704.0K | -1.6M |
Acquisitions | 0 | 0 | 0 | -365.2M | -13.7M |
Investment Purchases | - | - | - | -59.3M | - |
Investment Sales | - | 0 | 10.8M | - | - |
Investing Cash Flow | -95.0M | -2.2M | -590.8M | -423.8M | -15.1M |
Financing Activities | |||||
Share Repurchases | 0 | 0 | -31.6M | 0 | 0 |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 1.1B | 0 | 261.3M | 670.8M | 45.2M |
Debt Repayment | -310.9M | -44.6M | -143.6M | -57.0M | -7.1M |
Financing Cash Flow | 814.7M | -44.6M | 281.1M | 957.4M | 40.7M |
Free Cash Flow | -52.3M | 48.1M | -396.5M | -56.7M | -25.3M |
Net Change in Cash | -672.5M | -77.6M | -2.1B | 653.8M | 55.3M |
Cash Flow Trend
Core Scientific Key Financial Ratios
Valuation Ratios
Price to Sales
8.23
Profitability Ratios
Profit Margin
23.71%
Operating Margin
-28.13%
Return on Equity
160.33%
Return on Assets
-6.74%
Financial Health
Current Ratio
1.79
Debt to Equity
-1.09
Per Share Data
Book Value per Share
$-3.51
Revenue per Share
$1.12
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
corzz | 4.2B | - | - | 160.33% | 23.71% | -1.09 |
Microsoft | 3.8T | 39.67 | 11.86 | 33.61% | 35.79% | 32.63 |
Oracle | 659.0B | 54.06 | 32.20 | 82.38% | 21.68% | 519.59 |
Amdocs | 9.7B | 17.61 | 2.75 | 15.73% | 11.94% | 23.65 |
Klaviyo | 9.6B | -179.00 | 8.75 | -6.42% | -6.19% | 9.04 |
Shift4 Payments | 8.0B | 33.90 | 9.87 | 18.28% | 6.11% | 186.68 |
Financial data is updated regularly. All figures are in the company's reporting currency.